The company just closed its acquisition of J&J subsidiary DePuy Synthes’ Prodisc assets last week.
Fresh from its acquisition of Johnson & Johnson (NYSE:JNJ) subsidiary DePuy Synthes’ Prodisc assets, Centinel Spine last week reported raising more than $132 million.
In the waning days of 2017, Centinel it closed its acquisition of DePuy’s Prodisc-C, Prodisc-L, Prodisc-C Vivo, Prodisc-C Nova, Prodisc-O and Discover cervical and lumbar artificial disc systems. Although the purchase price remained undisclosed, Centinel said at the time that the deal was funded with debt and equity, with Piper Jaffray as its placement agent.
